Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

102 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Lapatinib for inflammatory breast cancer.
Hall PS, Hanby A, Cameron DA. Hall PS, et al. Lancet Oncol. 2009 Jun;10(6):538-9. doi: 10.1016/S1470-2045(09)70120-2. Lancet Oncol. 2009. PMID: 19482243 No abstract available.
Current perspective - trastuzumab.
Hall PS, Cameron DA. Hall PS, et al. Eur J Cancer. 2009 Jan;45(1):12-8. doi: 10.1016/j.ejca.2008.10.013. Epub 2008 Nov 29. Eur J Cancer. 2009. PMID: 19042123 Free article. Review.
Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial.
Cameron D, Brown J, Dent R, Jackisch C, Mackey J, Pivot X, Steger GG, Suter TM, Toi M, Parmar M, Laeufle R, Im YH, Romieu G, Harvey V, Lipatov O, Pienkowski T, Cottu P, Chan A, Im SA, Hall PS, Bubuteishvili-Pacaud L, Henschel V, Deurloo RJ, Pallaud C, Bell R. Cameron D, et al. Among authors: hall ps. Lancet Oncol. 2013 Sep;14(10):933-42. doi: 10.1016/S1470-2045(13)70335-8. Epub 2013 Aug 7. Lancet Oncol. 2013. PMID: 23932548 Clinical Trial.
Comparing Breast Cancer Multiparameter Tests in the OPTIMA Prelim Trial: No Test Is More Equal Than the Others.
Bartlett JM, Bayani J, Marshall A, Dunn JA, Campbell A, Cunningham C, Sobol MS, Hall PS, Poole CJ, Cameron DA, Earl HM, Rea DW, Macpherson IR, Canney P, Francis A, McCabe C, Pinder SE, Hughes-Davies L, Makris A, Stein RC; OPTIMA TMG. Bartlett JM, et al. Among authors: hall ps. J Natl Cancer Inst. 2016 Apr 29;108(9):djw050. doi: 10.1093/jnci/djw050. Print 2016 Sep. J Natl Cancer Inst. 2016. PMID: 27130929 Free PMC article. Clinical Trial.
Value of Information Analysis of Multiparameter Tests for Chemotherapy in Early Breast Cancer: The OPTIMA Prelim Trial.
Hall PS, Smith A, Hulme C, Vargas-Palacios A, Makris A, Hughes-Davies L, Dunn JA, Bartlett JMS, Cameron DA, Marshall A, Campbell A, Macpherson IR, Dan Rea, Francis A, Earl H, Morgan A, Stein RC, McCabe C; OPTIMA Trial Management Group. Hall PS, et al. Value Health. 2017 Dec;20(10):1311-1318. doi: 10.1016/j.jval.2017.04.021. Epub 2017 Jul 11. Value Health. 2017. PMID: 29241890 Free article. Clinical Trial.
6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial.
Earl HM, Hiller L, Vallier AL, Loi S, McAdam K, Hughes-Davies L, Harnett AN, Ah-See ML, Simcock R, Rea D, Raj S, Woodings P, Harries M, Howe D, Raynes K, Higgins HB, Wilcox M, Plummer C, Mansi J, Gounaris I, Mahler-Araujo B, Provenzano E, Chhabra A, Abraham JE, Caldas C, Hall PS, McCabe C, Hulme C, Miles D, Wardley AM, Cameron DA, Dunn JA; PERSEPHONE Steering Committee and Trial Investigators. Earl HM, et al. Among authors: hall ps. Lancet. 2019 Jun 29;393(10191):2599-2612. doi: 10.1016/S0140-6736(19)30650-6. Epub 2019 Jun 6. Lancet. 2019. PMID: 31178152 Free PMC article. Clinical Trial.
102 results